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http://www.biomedcentral.com/1471-2458/14/356RESEARCH ARTICLE Open AccessLongitudinal trends in prostate cancer incidence,
mortality, and survival of patients from two
Shanghai city districts: a retrospective
population-based cohort study, 2000–2009
Yi Hu1, Qi Zhao1, Jianyu Rao2, Haiju Deng3, Hong Yuan4 and Biao Xu1*Abstract
Background: Prostate cancer is the fifth most common cancer affecting men of all ages in China, but robust
surveillance data on its occurrence and outcome is lacking. The specific objective of this retrospective study was to
analyze the longitudinal trends of prostate cancer incidence, mortality, and survival in Shanghai from 2000 to 2009.
Methods: A retrospective population-based cohort study was performed using data from a central district (Putuo)
and a suburban district (Jiading) of Shanghai. Records of all prostate cancer cases reported to the Shanghai Cancer
Registry from 2000 to 2009 for the two districts were reviewed. Prostate cancer outcomes were ascertained by
matching cases with individual mortality data (up to 2010) from the National Death Register. The Cox proportional
hazards model was used to analyze factors associated with prostate cancer survival.
Results: A total of 1022 prostate cancer cases were diagnosed from 2000 to 2009. The average age of patients was
75 years. A rapid increase in incidence occurred during the study period. Compared with the year 2000, 2009
incidence was 3.28 times higher in Putuo and 5.33 times higher in Jiading. Prostate cancer mortality declined from
4.45 per 105 individuals per year in 2000 to 1.94 per 105 in 2009 in Putuo and from 5.45 per 105 to 3.5 per 105 in
Jiading during the same period. One-year and 5-year prostate cancer survival rates were 95% and 56% in Putuo,
and 88% and 51% in Jiading, respectively. Staging of disease, Karnofsky Performance Scale Index, and selection of
chemotherapy were three independent factors influencing the survival of prostate cancer patients.
Conclusions: The prostate cancer incidence increased rapidly from 2000 to 2009, and prostate cancer survival rates
decreased in urban and suburban Chinese populations. Early detection and prompt prostate cancer treatment is
important for improving health and for increasing survival rates of the Shanghai male population.
Keywords: Prostate cancer, Incidence, Mortality, Survival, ChinaBackground
Data from the Global Estimates of Cancer 2008 [1] indicate
that the age standardized incidence rate (ASR) of prostate
cancer in China was 4.3 per 105. This rate was much lower
than the rates in European and American countries [e.g.,
United States (ASR of 83.8 per 105)] and was also lower
compared with other Asian countries [e.g., Singapore (ASR* Correspondence: bxu@shmu.edu.cn
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unless otherwise stated.of 20.0 per 105)]. Meanwhile, the current increasing trend
compared with 2002 (1.7 per 105) [2] has begun to exceed
the rates in some neighboring countries [e.g., India (ASR of
3.4 per 105), Thailand (ASR of 4.2 per 105), and Bangladesh
(ASR of 1.7 per 105)]. However, because of the limitations
of the cancer registration database, there is very limited de-
tailed information on prostate cancer incidence and sur-
vival in the Chinese population. Remarkable social and
economic development, population aging, and life style
changes have occurred in China [3]. Therefore, it is im-
portant to identify the observed increasing trends ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fined geographic populations.
Shanghai is one of the most developed Chinese cities.
Vital statistical data have been available for decades, but
the Shanghai Cancer Registry has only been in operation
since 1972. There is a well-developed, community-based
cancer management system in Shanghai, wherein most
cancer patients are monitored by local community
health providers. The cancer management system facili-
tates longitudinal prostate cancer trend analysis of inci-
dence, mortality, and survival.
The objective of this study was to describe longitudinal
trends of prostate cancer incidence and mortality, to de-
termine survival status, and to identify factor(s) associ-
ated with treatment outcomes. Ten years (2000 to 2009)
of Cancer Registry data for two Shanghai districts were
used for the analysis.
Methods
Study sites and subjects
This retrospective population-based cohort study was
carried out in Putuo and Jiading, 2 of the 7 districts in
Shanghai. The districts were selected retrospectively
based on population characteristics and willingness to
participate in the study. Putuo is an industrial area with
a resident population of 870,046 individuals in 2009.
Jiading is located in a Shanghai suburb and had a popu-
lation of 546,907 individuals in 2009. The two selected
Shanghai areas reflected the composition of the urban
and suburban resident populations of the city.
The study subjects were resident prostate cancer pa-
tients reported during 2000–2009 in these two districts.
Only local Shanghai residents were reported to the
Shanghai Cancer Registry. Migrant and temporary resi-
dents were not included in the study cohort.
The study protocols were approved by the ethics com-
mittee of the School of Public Health, Fudan University
(institutional review board-approved protocol number:
#04-03-0011).
Data source
Information on prostate cancer patients was extracted
from three databases (i.e., the Shanghai Cancer Registry,
the Shanghai Cancer Follow-up database, and the Shanghai
Vital Statistics database at the district Center for Disease
Prevention and Control (CDC)). Incident cancer cases
were reported by Shanghai hospitals to the district CDC
and were registered in the Cancer Registry. The identified
cases were verified by community health center personnel,
and the follow-up data were managed by the CDC. Infor-
mation in the Cancer Registry database included the pa-
tient’s demographic and cancer diagnosis (both clinical and
pathologic diagnosis if applicable) data. The cancer-related
data included information on disease severity (clinicalstage), primary treatment, and active patient follow-up of
vital status. Follow-up data included cause of death. To en-
sure completeness, registry staff validated hospital dis-
charge and death certificate data for registered cases.
Prostate cancer death statistics (2000–2010) were extracted
from the district CDC Shanghai Vital Statistics database
and included age-specific information. The Karnofsky
score (KPS) was used to assess quality of life characteris-
tics. The KPS described the ability of each patient to carry
out activities on a scale of 0 to 100%. Cancer stage was
assessed using the American Urological Association (AUA)
prostate cancer staging system [4]. Stages 1–4 were catego-
rized based on primary tumor size relative to prostate size,
and involvement of adjacent structures.
Estimation of incidence and mortality
Considering the differences in population age structure
among countries and among different areas in China, age-
adjusted incidence and mortality rates of prostate cancer
(for all ages) were calculated using the world standard popu-
lation age distribution (World Health Organization, 2000)
and the national standardized population (China Population
Census, 2000). Results were presented as the world stan-
dardized rate (WSR) per 105 and the national standardized
rate (NSR) per 105. The mortality/incidence (M/I) ratio was
calculated using the crude and the standardized rates. Rela-
tive percentage survival was estimated using 1−mortality Mð Þincidence Ið Þ .
The ratio, 1−MI , is typically, but not always, a number be-
tween 0 and 100%. A value of 0% indicated extremely poor
survival, and a value of 100% indicated excellent survival [5].
Tests for trends in incidence and mortality
To estimate the longitudinal prostate cancer trends in the
two districts, the estimated annual percentage change
(EAPC) and 95% confidence intervals (CIs) for incidence
and mortality were calculated [6,7]. Using calendar year as
a regression variable, a linear regression model was applied
to describe the overall changes in trend by fitting the par-
ameter using the equation y =mx + b, where y was ln
(rate), and x was the calendar year. Based on the assump-
tion that the null hypothesis of the EAPC= 0 was equiva-
lent to the null hypothesis of the slope of the regression
line = 0, EAPC = 100× (em ‐ 1) and the 95% CI of EAPC =
100× (em ± SEm− 1) . The standard error of m (SEm) was
obtained from the fit of the regression line. This calculation
assumed that the rates increased or decreased at a constant
rate over the entire period. Statistical significance was
assessed using the two-tailed test at a given test level.
Data analysis of survival
Yearly and 5-year survival rates after prostate cancer
diagnosis were calculated and stratified by disease sever-
ity and age at diagnosis. Survival times were measured
Table 1 Clinical characteristic of prostate cancer patients
during 2000–2009 in Putuo and Jiading
Variable Putuo (n = 677) Jiading (n = 345)
No. % No. %
Vital status at the end of 2010
Alive 391 57.8 188 54.5
Dead of all causes 286 42.2 157 45.5
AUA staginga
1 139 25.8 76 27.6
2 148 27.5 73 26.5
3 97 18.0 54 19.6
4 155 28.7 72 26.3
TNM staging system
T Stageb
T1 81 39.7 43 45.3
T2 67 32.8 33 34.7
T3 31 15.2 11 11.6
T4 25 12.3 8 8.4
N stagec
N0 152 77.9 260 93.9
N1 33 16.9 12 4.3
N2 8 4.1 5 1.8
N3 2 1.1 0 0.0
M staged
M0 151 71.9 268 96.1
M1 59 28.1 11 3.9
Treatment by prostatectomy
None 141 20.8 17 4.9
Prostatectomy 233 34.4 202 58.6
Palliative treatment 26 3.9 18 5.2
Others 277 40.9 108 31.3
aAUA staging information was missing from 138 patients in Putuo and 70
in Jiading.
bT staging information was missing from 473 patients in Putuo and 250 Jiading.
cN staging information was missing from 482 patients in Putuo and 68 in Jiading.
dM staging information was missing from 467 patients in Putuo and 66 in Jiading.
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Yearly survival rates and effects of prognostic covariates
were evaluated using the Kaplan–Meier method and the
log-rank test within strata defined by age (50–59, 60–69,
70–79, and ≥80), treatment, and KPS (0–50, 50–80, and
80–100) categories. The hazard ratio (HR) and 95% CI
were estimated using a multivariate Cox proportional
hazard model. A p-value < 0.05 was considered to be sta-
tistically significant. All tests were performed using SPSS
11.0 (SPSS, Chicago, IL, USA).
Results
Demographic and clinical characteristics of prostate
cancer patients
A total of 1022 (677 in Putuo and 345 in Jiading) pros-
tate cancer cases aged ≥20 years were identified for the
2000–2009 period, with 43.9% in Putuo and 40.5% in
Jiading under 60 years of age. The median age at diagno-
sis was 75 years (interquartile range: 71–80 years) in
Putuo and 75 years (interquartile range:68–80 years) in
Jiading (ICD-10 code = C61). For T, N, and M staging,
there were 69.8%, 71.2%, and 69.0% missing in Putuo
and 72.5%, 19.7%, and 19.1% missing in Jiading, respect-
ively. Overall, 39.7%, 32.8%, 15.2%, and 12.3% of patients
had stage T1, T2, T3, and T4 disease in the Putuo dis-
trict, and 45.3%, 34.7%, 11.6%, and 8.4% of patients had
stage T1, T2, T3, and T4 disease in the Jiading district,
respectively. Tumor cells were present in the regional or
distant lymph nodes in 22.1% of the patients from Putuo
and 6.1% of the patients from Jiading (Table 1). Of the
814 patients (539 in Putuo, 275 in Jiading) for whom sta-
ging information was available, the distributions of AUA
stages 1–4 were 25.8%, 27.5%, 18.0%, and 28.7% in the
Putuo patients, and 27.6%, 26.5%, 19.6%, and 26.3% in
the Jiading patients, respectively.
After diagnosis, 34.4% (233/677) of the patients from
Putuo and 58.6% (202/345) of the patients from Jiading
obtained a prostatectomy, and 141 (20.8%) and 17 (4.9%)
of the patients received no cancer-specific treatment.
The analysis of the vital statistics data received from the
district CDCs revealed that 391 (57.8%) of the patients
from Putuo and 188 (54.5%) of the patients from Jiading
were alive in December, 2010.
Trend and point estimation of incidence, mortality, and
relative survival
The results for the analysis of longitudinal trends of
prostate cancer incidence indicated that there was a re-
markable increase in incidence in Putuo and Jiading
(Figure 1). In Putuo, the crude incidence rate (CIR) for
prostate cancer increased steadily (EAPC = 13.0%; 95%
CI: 9.6–16.5%) from 2000–2009. There was a similar
total increase in Jiading (EAPC = 14.1%; 95% CI: 12.4–
15.9%). However, the increase in Jiading mainly occurredfrom 2000–2002 and 2008–2009, and there was little
change in CIR from 2003–2008. There were similar trends
for NSR and WSR. The EAPCs for NSR and WSR were
7.7% (95% CI: 4.0–11.5%) and 8.5% (95% CI: 5.0–12.2%) in
Putuo and 9.1% (95% CI: 7.3–11.0%) and 10.1% (95% CI:
8.2–12.0%) in Jiading, respectively (Table 2).
Prostate cancer mortality rates varied greatly throughout
the study period in both of the districts. The highest rate
(8.36 per 105) in Putuo occurred in 2005 (Figure 2). In
Jiading, the highest mortality rate (11.25 per 105) occurred
in 2002. However, there was a general decrease in trend,
with an EAPC of −33.1% (95% CI: −20.1 to −45.2%) in
Putuo and −15.4% (95% CI: −10.7 to −27.4%) in Jiading.
Figure 1 Trend of prostate cancer national standardized rate of incidence and mortality in the male population during 2000–2009.
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in Putuo and −20.0% in Jiading) and WSR (−39.2% in
Putuo and −10.9% in Jiading; Table 2).
In general, the relative survival rate increased in both
of the districts. The EAPC was 6.2% for the crude (95%
CI: 3.8–8.7%), NSR (95% CI: 4.0–9.1%), and WSR (95%
CI: 4.0–8.4%) estimates in Putuo and was 5.8% (95% CI:
3.9–7.7%), 6.7% (95% CI: 5.4–8.0%) and 6.7% (95% CI:
5.6–7.9%) for the three estimates, respectively, in Jiading
(Table 3).
Throughout the study period, the 60–70 year age
group accounted for the highest proportion of incidence,
ranging from 57.0% in 2004 to 46.0% in 2009. A poten-
tial increasing trend in incidence occurred in the 50–60Table 2 Estimated annual percentage change (EAPC) of prost
Jiading and Putuo
Rates Putuo district
M SEm EAPC (%) p 95% CI (%)
Incidence
Crude 0.122 0.031 13.0 0.005a 9.6 ~ 16.5
NSR 0.074 0.035 7.7 0.067 4.0 ~ 11.5
WSR 0.082 0.033 8.5 0.038a 5.0 ~ 12.2
Mortality
Crude −0.402 0.328 −33.1 0.253 −20.1 ~ −45
NSR −0.272 0.168 −23.8 0.144 −12.7 ~ −41
WSR −0.498 0.292 −39.2 0.127 −23.7 ~ −45
Relative survival
Crude 0.060 0.023 6.2 0.031a 3.8 ~ 8.7
NSR 0.063 0.024 6.2 0.031a 4.0 ~ 9.1
WSR 0.060 0.021 6.2 0.02a 4.0 ~ 8.4
ap < 0.05.year age group (EAPC = 40.1% (95% CI: 20.0–60.2%),
and this trend was statistically significant (p = 0.047)
(Figure 3).
AUA stage 1 and stage 2 cancers accounted for the
majority of the estimated incidence values. The highest
level of AUA stage 1 occurred in 2009 (47.1%), and the
highest level of AUA stage 2 occurred in 2001 (57.1%).
Meanwhile, there was a steady trend in stage 4 cancer
for proportion of incidence (EAPC = 8%; 95% CI: 6.9–
12.6%, p = 0.291).
Survival analysis
The results for analysis of life tables indicated that the
respective overall 1-year and 5-year survival rates wereate cancer incidence and mortality during 2000–2009 in
Jiading district
M SEm EAPC (%) p 95% CI (%)
0.132 0.015 14.1 0.0001a 12.4 ~ 15.9
0.096 0.017 9.1 0.001a 7.3 ~ 11.0
0.087 0.017 10.1 0.0001a 8.2 ~ 12.0
.2 −0.167 0.247 −15.4 0.517 −10.7 ~ −27.4
.7 −0.223 0.148 −20.0 0.172 −12.9 ~ −36.7
.7 −0.115 0.164 −10.9 0.503 −5.2 ~ −24.8
0.056 0.018 5.8 0.013a 3.9 ~ 7.7
0.065 0.012 6.7 0.001a 5.4 ~ 8.0
0.065 0.011 6.7 0.0001a 5.6 ~ 7.9
Figure 2 Trend of prostate cancer world standardized rate of incidence and mortality in the male population during 2000–2009.
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log-rank analysis revealed that there were significant dif-
ferences in prostate cancer survival rate between pa-
tients from these two districts (p = 0.043). The median
survival time was 5.16 years (95% CI: 5.02–6.18) in
Putuo and 5.06 years (95% CI: 4.94–5.93) in Jiading.Table 3 Cox Regression analysis on factors influencing surviv
Jiading and Putuo
Variables Putuo
Mean (95% CI) HR (95% CI)
Age at diagnosis (yrs)
50- 7.6(5.84-9.28) 1
60- 6.8(5.87-7.68) 1.4(0.59-3.09)
70- 6.3(5.84-6.74) 1.5(0.69-3.15)
80- 4.4(3.88-5.00) 2.4(1.13-5.28)
AUA Stage
1 6.9(6.05-7.76) 1
2 7.1(6.16-7.96) 1.0(0.55-1.82)
3 6.6(5.13-8.03) 1.1(0.51-2.36)
4 3.0(2.45-3.56) 3.9(2.33-6.57)
Curative treatment
None 6.4(5.76-7.06) 1
Prostatectomy 5.8(5.26-6.38) 1.1(0.76-1.51)
palliative treatment 7.1(5.49-8.78) 0.7(0.30-1.64)
Others 5.9(5.33-6.49) 1.3(0.94-1.83)
KPS
0- 1.3(0.82-1.74) 1
50- 3.1(2.29-3.96) 0.6(0.33-1.11)
80- 6.6(6.25-6.96) 0.3(0.17-0.48)
ap < 0.05.The results of the univariate analysis using log-rank
comparisons indicated that cancer stage, age, KPS, and
treatment methods were associated with survival. Fur-
thermore, a multivariate analysis using a Cox propor-
tional hazards model revealed that KPS and cancer stage
were independent predictive factors for prostate canceral of prostate cancer patients diagnosed in 2000–2009 in
Jiading
p Mean (95% CI) HR (95% CI) p
6.1(4.33-7.92) 1
0.477 5.5(4.50-6.42) 1.6(0.49-5.28) 0.438
0.323 6.0(5.25-6.69) 1.6(0.50-5.13) 0.428
0.023a 3.9(3.10-4.61) 2.5(0.75-8.04) 0.138
1 7.1(5.97-8.23) 1
0.987 5.7(4.64-6.69) 1.9(0.70-5.13) 0.209
0.810 4.0(2.89-5.07) 3.0(1.01-8.94) 0.049a
0.0001a 3.8(2.54-5.08) 2.84(1.03-7.81) 0.044a
4.1(1.91-6.19) 1
0.696 7(6.36-7.62) 0.5(0.19-0.93) 0.026a
0.419 6.1(4.77-7.49) 0.6(0.18-1.81) 0.342
0.106 2.7(1.97-3.38) 1.6(0.64-4.12) 0.314
4.6(3.21-5.89) 1
0.430 5.0(3.83-6.19) 0.6(0.26-1.16) 0.118
0.001a 5.0(4.41-5.60) 0.8(0.47-1.26) 0.299
Figure 3 The age and stage stratified distributions of prostate cancer incidence of each year.
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value >80 had a lower HR for death compared with pa-
tients with a KPS value of 0–50 (HR, 0.3; 95% CI: 0.17–
0.48). Compared with stage 1 patients, stage 3 and stage 4
patients from Jiading (HR3 = 3.0, 95% CI: 1.01–8.94; HR4 =
2.84, 95% CI: 1.03–7.81) and stage 4 patients from Putuo
(HR4 = 3.9, 95% CI: 2.33–6.57) had significantly higher
HRs for death.
Discussion
In the 1970s, Shanghai established a cancer registration
system that includes the entire resident population. The
city-wide cancer registration system documents cancer
cases for surveillance, management, and control pur-
poses. The present study used data from this system to
determine the longitudinal trends in prostate cancer,
including incidence, mortality, and survival status.
The results of this study indicated that there was a
trend toward an increased prostate cancer incidence in
Shanghai during the past decade. Interpretation of pros-
tate cancer incidence time trends must consider expo-
sure risk factors, population shifts, improvement in case
detection, and the impact of PSA screening of asymp-
tomatic patients. The well-established risk factors for
prostate cancer are age, race/ethnicity [8], family history
[9,10], diet [11,12] and obesity [13,14]. Population demo-
graphics are changing significantly in China in associ-
ation with economic development, especially in urban
areas. The proportion of men older than age 65 was
6.71% in Shanghai in 2000 and increased to 16.6% in
2012. Male life expectancy also increased from 78.77 to
79.82 years. Regardless of age adjustment, this trendindicating increased prostate cancer incidence suggests
that the number of prostate cancer cases have increased
over the past ten years. There have also been lifestyle
changes in the relatively rich cities such as Shanghai,
which are reflected by an increased obesity burden.
Obesity and overweight have become epidemic in urban
populations in China [15], and have been proven to be
associated with an increased risk of cancer [16], diabetes
[17] and hypertension [18]. The increase in prostate can-
cer incidence in Shanghai might be attributable to the
fat-rich diet consumed by the population.
Technology advances and better access to health care
are important for the improvement of cancer detection.
The increase in prostate cancer incidence might be a re-
sult of the application of echo-guided biopsy and PSA
testing in symptomatic or asymptomatic patients. There
is currently no active PSA screen program in Shanghai,
but PSA testing is widely used, especially in older men
who present with urological symptoms. As reflected in
this study population, most of the patients who receive
PSA testing are symptomatic. The availability of univer-
sal health care coverage for Shanghai residents also likely
has contributed to the healthcare community’s height-
ened awareness of prostate cancer symptoms. Therefore,
changing dietary habits and improved access to health
care (including PSA testing) may have contributed to
the increased prostate cancer incidence observed in this
study. However, the exact contribution of each factor is
difficult to quantify.
A relative reduction in mortality from prostate cancer
was a finding from our study. This reduction could be
explained by improvements in diagnosis and/or early
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tomy [19,20]. The results of our study indicated that
there was a trend towards early prostate cancer detec-
tion. The proportion of stage 1 cancer was 42% in 2009
and was 20% in 2001. High 5-year survival rates have been
reported for localized prostate cancers (stage 1 or 2)
[21,22], most likely because there are a number of effective
treatment options (e.g., radical prostatectomy, radiation).
Mortality from high stage disease increases substantially
when therapeutic options are rather limited. The results
of Scandinavian Prostate Cancer Group Study Number 4
[22] indicated that there was an absolute reduction in
mortality of 6 percentage points among men who under-
went radical prostatectomy. Similarly, the results of our
study suggest that radical prostatectomy reduced prostate
cancer mortality. Taken together, these observations in-
dicate that early detection and proper treatment could
reduce the prostate cancer mortality. However, over-
diagnosis and subsequent treatment may result in side ef-
fects (e.g., incontinence and impotence), and adversely
affect quality of life.
It was striking to find that compared with the indus-
trial countries that have high rates of survival from pros-
tate cancer, the 1-year and 5-year survival rates were
only 95% and 56% in Putuo, and 88% and 51% in Jiading,
respectively. The median survival time was approxi-
mately 5 years in both districts. Findings from this analysis
also suggest that an initial treatment using prostatectomy
and/or chemotherapy may potentially be associated with
prolonged survival. Surgery might be effective for the pre-
vention of the spread of prostate cancer. A history of
chemotherapy was a predictor that was associated with
improved survival in patients undergoing surgery, com-
pared with patients without any treatment. The survival
benefit from chemotherapy could be due to tumor cell de-
struction during prior chemotherapy. Baseline differences
in KPS and staging did have an effect on survival. Prostate
cancer patients with KPS ≥ 80 and tumors graded at below
a stage 3 were more likely to survive. These characteristics
are consistent with less pathologically aggressive disease
and a smaller tumor mass [23]. These findings suggest
that more efforts should be aimed at early detection of
symptomatic patients, and that treatment effects should
be verified systematically. Progression in disease pathology
should be well documented, and appropriate treatment
follow-up is critical.
There has recently been much debate on the need for
prostate cancer intervention programs in industrialized
countries because it seemed as if early detection and
cure were no longer problems in these countries. Almost
one-half of the patients included in this study died
within five years after diagnosis, which indicates that the
value of early detection intervention deserves further
discussion. However, most of the patients were oldermen, so over-diagnosis is a greater concern because of
their limited life expectancy. This observation and the
findings of the stable trend in incidence in the younger
group and the increasing trend in relative survival sug-
gest that a prostate screening program might have li-
mited effects.
The results of this study also revealed that there was
an increasing trend in cancer stages 1 and 2. Surgery
and chemotherapy do improve survival among prostate
cancer patients, and it is likely that treatment with the
intention to cure has contributed to the reductions in
mortality. Educational programs that instill adequate
awareness of early symptoms of prostate cancer in spe-
cial high risk populations (e.g., males >70 years of age)
should be developed and implemented. Early prostate
cancer detection should improve when the urban popu-
lation is well-formed.
There were some limitations of this study. Especially
for the subjects enrolled in 2009, follow-up time might
have not been sufficient for adequate evaluation of out-
comes. Therefore, mortality might have been slightly
underestimated. The pathological diagnosis (TNM sta-
ging) was missing from the records for a relatively high
proportion of subjects. Gleason score data were also not
included in the registry. Therefore, we were unable to
obtain a comprehensive understanding of prostate can-
cer pathology. Management of the Cancer Registry and
Cancer Follow-up databases should be changed so that
the quality of the system improves.
Conclusions
The world population adjusted incidence of prostate
cancer was relatively low in the Putuo and Jiading dis-
tricts of Shanghai in 2009. However, an increase in pros-
tate cancer incidence occurred between 2000 and 2009,
which included an estimated annual proportional change
of approximately 13.0% in Putuo and 14.1% in Jiading.
The prostate cancer survival rate was is disappointedly
low; the 5-year survival rate was 56% and 51% for Putuo
and Jiading districts, respectively. Health education on
early detection and prompt treatment of prostate cancer
is of great importance for improving health and prolong-
ing life of the adult male population in Shanghai.
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